Wells Fargo raised the firm’s price target on Verona Pharma (VRNA) to $138 from $107 and keeps an Overweight rating on the shares. The firm says its survey of high volume COPD prescribers implies that despite strong stock performance year-to-date, shares remain among the most undervalued in its coverage.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Strong Buy Rating for Verona Pharma’s Ohtuvayre Amidst Undervalued Peak Sales Potential and Growing Market Demand
- Verona Pharma price target raised to $116 from $92 at Roth Capital
- Verona Pharma price target raised to $100 from $90 at Cantor Fitzgerald
- Verona Pharma price target raised to $110 from $95 at Jefferies
- Verona Pharma management to meet with Piper Sandler